[{"orgOrder":0,"company":"EYEGENE","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"EG-COVID-003","moa":"SARS-CoV-2 spike protein","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"EYEGENE","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"EYEGENE \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"EYEGENE \/ Novotech"},{"orgOrder":0,"company":"EYEGENE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Virus-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"EG-COVII","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"EYEGENE","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EYEGENE \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EYEGENE \/ Undisclosed"},{"orgOrder":0,"company":"EYEGENE","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"EG-HZ-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"EYEGENE","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"EYEGENE \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"EYEGENE \/ Novotech"},{"orgOrder":0,"company":"EYEGENE","sponsor":"BMI Korea","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"EYEGENE","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"EYEGENE \/ BMI Korea","highestDevelopmentStatusID":"9","companyTruncated":"EYEGENE \/ BMI Korea"}]